Fate Therapeutics Inc. (NASDAQ:FATE) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Scott Wolchko - President and CEO Ed Dulac - CFO Yu-Waye Chu - Chief Medical Officer Conference Call Participants Tazeen Ahmad - Bank of America Kelsey Goodwin - Guggenheim Securities Tyler Van Buren - Cowen Ashiq Mubarack - Citigroup Michael Yee - Jefferies James Shin - Abbott Matt Biegler - Oppenheimer Daina Graybosch - SVB Securities Robyn Kay Karnauskas - Truist Securities Operator Welcom ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock FATE Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to . Commission File Number 001-36076 (Exact name of reg ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2022 Earnings Conference Call May 4, 2022 5:00 PM ET Company Participants Bob Valamehr - Chief Research & Development Officer Scott Wolchko - Founder, President & Chief Executive Officer Ed Dulac - Chief Financial Officer Wayne Chu - Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Yigal Nochomovitz - Citigroup Daina Graybosch - SVB Securities Nick Abbott - Wells Fargo Kelsey Goodwin - Guggenheim Mara Goldstein - Mizuho Robyn Karnauskas - Tr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to . Commission File Number 001-36076 FATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 65-1311552 (State or other jurisdiction of incor ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2021 Earnings Conference Call February 28, 2022 5:00 PM ET Company Participants Scott Wolchko - President and Chief Executive Officer Wayne Chu - Chief Medical Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research and Development Officer Conference Call Participants Michael Yee - Jefferies Ashiq Mubarack - Citi Daina Graybosch - SVB Leerink Kelsey Goodwin - Guggenheim Nick Abbott - Wells Fargo Matt Biegler - Oppenheimer Robyn Karnauskas - Truist Se ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-36076 FATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 65-1311552 (State or o ...

Better Cells For Better Therapies™ | --- | --- | |-------------------------------------|-------| | | | | Programmed Cellular Immunotherapies | | - Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the safety and therapeutic potential of the Company's product candidates, the advancement of and plans and timelines related to the Company's ongoing and planned clinical stud ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q3 2021 Earnings Conference Call November 4, 2021 5:00 PM ET Company Participants Scott Wolchko - President and CEO Ed Dulac - CFO Wayne Chu - SVP, Clinical development Conference Call Participants Michael Yee - Jefferies Mike Ulz - Morgan Stanley Alethia Young - Cantor Peter Lawson - Barclays Daina Graybosch - SVB Srikripa Devarakonda - Truist Securities Matt Biegler - Oppenheimer Mara Goldstein - Mizuho Nick Abbott - Wells Fargo Ted Tenthoff - Piper Sandler Rob Burns ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to . Commission File Number 001-36076 FATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 65-1311552 (State or other jurisdiction of i ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q2 2021 Earnings Conference Call August 4, 2021 5:00 PM ET Company Participants Scott Wolchko - President and CEO Ed Dulac - CFO Conference Call Participants Yigal Nochomovitz - Citi Michael Schmidt - Guggenheim Alethia Young - Cantor Fitzgerald Michael Yee - Jefferies Daina Graybosch - SVB Leerink Ben Burnett - Stifel Peter Lawson - Barclays Matt Biegler - Oppenheimer Mara Goldstein - Mizuho Srikripa Devarakonda - Truist Securities Nick Abbott - Wells Fargo Operator We ...